An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) + Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Pimurutamab (Primary) ; Serplulimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Shanghai Henlius Biotech
Most Recent Events
- 25 Apr 2022 Status changed from not yet recruiting to recruiting.
- 22 Feb 2022 New trial record